Dose-finding of PB-119 Administered Subcutaneously Once-weekly Versus Placebo in Drug-naïve T2DM Subjects

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 251 participants.

Also called NCT03520972

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; triple masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 251 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT03520972
Other papers using this trial's data
  • Efficacy and safety of PEGylated exenatide injection (PB-119) in treatment-naive type 2 diabetes mellitus patients: a Phase II randomised, double-blind, parallel, placebo-controlled study Diabetologia, 2021-05 DOI, PubMed 33687487, PMC8012337 PubMed links an erratum for this paper. Erratum: PMID 34037812 In the PMC Open Access subset under CC BY.

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
China (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT03520972. Randomized; triple masking; primary purpose treatment. Start 2018-06-05 (actual); primary completion 2019-07-29 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Dose-finding of PB-119 Administered Subcutaneously Once-weekly Versus Placebo in Drug-naïve T2DM Subjects
Condition
Type 2 Diabetes Mellitus
Intervention (Drug)
PB-119 75ug
Intervention (Drug)
PB-119 150ug
Intervention (Drug)
PB-119 200ug
Intervention (Drug)
placebo
Lead sponsor
PegBio Co., Ltd. (class: other)
Collaborator
Tigermed Consulting Co., Ltd (class: industry)

Record details

Record id
cardio:ct-nct03520972
Content hash
0ee254fdab47912f384e7b0f017ca10506b0a979f898d64f71fcd5b0a3589795